ReviewWorld journal of hepatology2015
Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives.
Review in World journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Targeting inflammatory pathways in hepatocellular carcinoma: recent developments.Discover oncology · 2025Review
- Matrin-3 acts as a potential biomarker and promotes hepatocellular carcinoma progression by interacting with cell cycle-regulating genes.Cell cycle (Georgetown, Tex.) · 2024Article
- Treatment Patterns and Recommendations for Improving the Management of Hepatocellular Carcinoma in Saudi Arabia.Journal of hepatocellular carcinoma · 2024Article
- Article
- Overlap syndrome of autoimmune hepatitis and primary biliary cholangitis complicated with atypical hepatocellular carcinoma: a case report.Journal of medical case reports · 2023Article
- Targeting Glutamine Metabolism with a Novel Na+/K+-ATPase Inhibitor RX108 in Hepatocellular Carcinoma.Molecular cancer therapeutics · 2023Article
- Current Status of Management of Hepatocellular Carcinoma in The Gulf Region: Challenges and Recommendations.Cancers · 2023Review
- Patients with hepatocellular carcinoma that die during the first year of liver transplantation have high blood sFasL concentrations.World journal of clinical cases · 2023Article
- METTL3 promotes m6A hypermethylation of RBM14 via YTHDF1 leading to the progression of hepatocellular carcinoma.Human cell · 2022Article
- Article
- Article
- DNA and RNA oxidative damage in hepatocellular carcinoma patients and mortality during the first year of liver transplantation.World journal of hepatology · 2022Article
- Tumor Microenvironment of Hepatocellular Carcinoma: Challenges and Opportunities for New Treatment Options.International journal of molecular sciences · 2022Review
- Article
- [Diagnostic and prognostic significance of α-fetoprotein in hepatocellular carcinoma].Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen · 2020Article
- CircRNA CDR1as/miR-1287/Raf1 Axis Modulates Hepatocellular Carcinoma Progression Through MEK/ERK Pathway.Cancer management and research · 2020Article
- Low Serum Melatonin Levels Prior to Liver Transplantation in Patients with Hepatocellular Carcinoma are Associated with Lower Survival after Liver Transplantation.International journal of molecular sciences · 2019Article
- Paradoxical effects of cellular senescence-inhibited gene involved in hepatocellular carcinoma migration and proliferation by ERK pathway and mesenchymal-like markers.OncoTargets and therapy · 2019Article
- New prognostic biomarkers of mortality in patients undergoing liver transplantation for hepatocellular carcinoma.World journal of gastroenterology · 2018Review
- Cancer prevention through miRNAs: miR-206 prevents the initiation and progression of hepatocellular carcinoma by attenuating c-MET signaling and cell-cycle progression via cyclin D1 and CDK6.Non-coding RNA investigation · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is the most common liver-derived malignancy with a high fatality rate. Risk factors for the development of HCC have been identified and are clearly described. However, due to the lack of tumor-specific symptoms, HCC are diagnosed at progressed tumor stages in most patients, and thus curative therapeutic options are limited. The focus of this review is on surgical therapeutic options which can be offered to patients with HCC with special regard to recent findings, not exclusively focused on surgical therapy, but also to other treatment modalities. Further, potential promising future perspectives for the treatment of HCC are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.